Stephen O'Rahilly Selected Research

Obesity

10/2008	Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity.
09/2007	Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3.
09/2006	Heterozygosity for a POMC-null mutation and increased obesity risk in humans.
08/2005	Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity.
09/2004	Studies of the peptide YY and neuropeptide Y2 receptor genes in relation to human obesity and obesity-related traits.
06/2004	Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity.
05/2004	Melanin-concentrating hormone receptor mutations and human obesity: functional analysis.
05/2003	Association of polymorphisms in GPR10, the gene encoding the prolactin-releasing peptide receptor with blood pressure, but not obesity, in a U.K. Caucasian population.
03/2003	Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene.
03/2003	Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms.
10/2002	Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?
10/2002	Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.
08/2002	A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism.
04/2002	Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha.

Articles by Research Topic

Disease

14	Obesity 10/2008 - 04/2002
3	Insulin Resistance 05/2008 - 10/2006
3	Syndrome 03/2007 - 06/2003
2	Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy) 04/2008 - 07/2004
1	Hyperphagia 09/2007
1	Hypersensitivity (Allergy) 07/2007
1	Body Weight (Weight, Body) 12/2006
1	Anorexia 05/2006
1	Metabolic Diseases (Metabolic Disease) 03/2006
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2006
1	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 11/2004
1	Bulimia (Binge Eating) 08/2003
1	Prader-Willi Syndrome (Syndrome, Prader-Willi) 01/2003
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2002

Drug/Important Bio-Agent (IBA)

5	LeptinIBA 10/2008 - 10/2002
4	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 07/2007 - 08/2002
3	PPAR gammaIBA 10/2006 - 06/2003
3	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 08/2003 - 03/2003
2	AdiponectinIBA 05/2008 - 06/2007
2	Insulin ReceptorIBA 05/2008 - 06/2007
1	LigandsIBA 10/2008
1	Caveolin 1IBA 04/2008
1	Proprotein Convertase 1IBA 09/2007
1	CorticosteroneIBA 07/2007
1	AntibodiesIBA 06/2007
1	Lamin Type A (Lamin A)IBA 03/2007
1	PeptidesIBA 12/2006
1	DNA (Deoxyribonucleic Acid)IBA 10/2006
1	Tamoxifen FDA LinkGeneric 05/2006
1	Fatty Acid Synthetase Complex (Fatty Acid Synthase)IBA 05/2006
1	Malonyl Coenzyme A (Malonyl CoA)IBA 05/2006
1	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA 01/2006
1	rosiglitazone (Avandia)FDA Link 11/2004
1	neuropeptide Y2 receptorIBA 09/2004
1	Peptide YYIBA 09/2004
1	Serotonin (5 Hydroxytryptamine)IBA 06/2004
1	melanin-concentrating hormone receptorIBA 05/2004
1	prolactin-releasing peptide receptorIBA 05/2003
1	Insulin (Novolin)FDA Link 01/2003
1	GhrelinIBA 01/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2002